Special Issue

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression

Message from the Guest Editor

Development of resistance to standard therapies represents the leading cause of cancer recurrence and death. Several biological events are involved in the development of drug resistance: growth factor receptors, transcription factors, metabolic rewiring, miRNA expression and transfer, drug extrusion, cancer stem cell enrichment, communication between tumor cells and their microenvironment (stromal, endothelial and immune cells), gut microbiome activity. In this setting, circulating cancer cells and tumor DNA, cancer cell secretome and tumor-derived extracellular vesicles can be easily isolated from patient body fluids, representing innovative biomarkers of treatment response and tumor relapse. Thus, liquid biopsies are currently considered as an interesting tool for cancer detection but also to define the proper antitumor treatment regimens. In this issue, we will describe the molecular mechanisms underlying the development of drug resistance in cancer and discuss the new therapeutic strategies aimed at preventing tumor progression and recurrence.

Guest Editor

Prof. Dr. Patrizia Limonta

Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, via Balzaretti 9, 20133 Milano, Italy

Deadline for manuscript submissions

closed (15 April 2021)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/47066

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)